- Molecular NameOlanzapine
- Synonymolanzapine
- Weight312.441
- Drugbank_IDDB00334
- ACS_NO132539-06-1
- Show 2D model
- LogP (experiment)3.0
- LogP (predicted, AB/LogP v2.0)2.73
- pka5.0,7.4
- LogD (pH=7, predicted)1.87
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-2.67
- LogSw (predicted, AB/LogsW2.0)0.74
- Sw (mg/ml) (predicted, ACD/Labs)0.06
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA59.11
- StatusFDA approved
- Administrationoral, intramuscular
- PharmacologyAn atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
- Absorption_value100.0
- Absorption (description)Well absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.
- Caco_2N/A
- Bioavailability60.0
- Protein binding93.0
- Volume of distribution (VD)16.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (direct glucuronidation and CYP mediated oxidation)
- Half life33.1 h
- Excretionurine 57%, feces 30%
- Urinary Excretion7.3
- Clerance6.2 ml/min/kg
- ToxicityThe most commonly observed adverse events associated with the use of oral olanzapine (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (olanzapine incidence at least twice that for placebo) were: for schizofrenia - postural hypotension, constipation, weight gain, personality disorder (the term for designating non-aggressive objectionable behavior), akathisia; for bipolar mania - asthenia, dry mouth, constipation, dyspepsia, increased appetite, somnolence, dizziness, tremor.
- LD50 (rat)N/A
- LD50 (mouse)N/A